Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer

Endocrine-Related Cancer

Volumn 18, Issue 6, 2011, Pages 721-730

  Bedard, Philippe L ^a   Singhal, Sandeep K ^b   Ignatiadis, Michail ^b   Bradbury, Ian ^c,d   Haibe Kains, Benjamin ^b,e,i,j   Desmedt, Christine ^b   Loi, Sherene ^b   Evans, Dean B ^f   Michiels, Stefan ^b   Michael Dixon, J ^g   Miller, William R ^h   Piccart, Martine J ^b   Sotiriou, Christos ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b JULES BORDET INSTITUTE   (Belgium)

^c FRONTIER SCIENCE SCOTLAND LTD   (United Kingdom)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Breakthrough Breast Research Group   (United Kingdom)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LETROZOLE; RNA; SOMATOMEDIN C;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; GENE EXPRESSION; GENE EXPRESSION GRADE INDEX; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; ONCOGENE; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PREDICTIVE VALUE; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; CELL SURVIVAL; EARLY DETECTION OF CANCER; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASM, RESIDUAL; NITRILES; PROGNOSIS; RECEPTORS, ESTROGEN; TIME FACTORS; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84855916374     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-11-0180     Document Type: Article

References (38)

1. Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF et al. 2006 Reproducibility of gene expression signature-based predictions in replicate experiments. Clinical Cancer Research 12 1721-1727. (doi:10.1158/1078-0432.CCR-05-1539)
2. Assersohn L, Salter J, Powles TJ, A'Hern R, Makris A, Gregory RK, Chang J & Dowsett M 2003 Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Research and Treatment 82 113-123. (doi:10.1023/B:BREA.0000003968.45511.3f)
3. Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G et al. 2009 Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 27 2630-2637. (doi:10.1200/JCO.2008.18.8391)
4. Chang HY 2005 Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. PNAS 102 3738-3743. (doi:10.1073/pnas.0409462102)
5. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS et al. 2009 Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. Journal of the National Cancer Institute 101 736-750. (doi:10.1093/jnci/djp082)
6. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O et al. 2004 A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine 350 1081-1092. (doi:10.1056/NEJMoa040331)
7. Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK & Lee AV 2008 Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. Journal of Clinical Oncology 26 4078-4085. (doi:10.1200/JCO.2007.13.4429)
8. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M & Sotiriou C 2008 Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clinical Cancer Research 14 5158-5165. (doi:10.1158/1078-0432.CCR-07-4756)
9. Dixon JM, Renshaw L, Bellamy C, Stuart M, Hoctin-Boes G & Miller WR 2000 The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, singlecenter study. Clinical Cancer Research 6 2229-2235. (Pubitemid 30399188)
10. Dowsett M & Dunbier AK 2008 Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer. Clinical Cancer Research 14 8019-8026. (doi:10.1158/1078-0432.CCR-08-0974)
11. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, Salter J, Detre S, Hills M & Walsh G 2007 Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. Journal of the National Cancer Institute 99 167-170. (doi:10.1093/jnci/djk020)
12. Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA et al. 2001 Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Annals of Oncology 12 1527-1532. (doi:10.1023/A:1013128213451)
13. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS & Baum M 2008 Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncology 9 45-53. (doi:10.1016/S1470-2045(07)70385-6)
14. Forouhi P, Walsh JS, Anderson TJ & Chetty U 1994 Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment. British Journal of Surgery 81 223-225. (doi:10.1002/bjs. 1800810221)
15. Gee J, Robertson J, Gutteridge E, Ellis I, Pinder S, Rubini M & Nicholson R 2005 Epidermal growth factor receptor/ HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocrine-Related Cancer 12 S99. (doi:10.1677/erc.1.01005)
16. Going JJ 1994 Efficiently estimated histologic cell counts. Human Pathology 25 333-336. (doi:10.1016/0046-8177(94)90139-2)
17. Hedenfalk I, Ringnér M, Ben-Dor A, Yakhini Z, Chen Y, Chebil G, Ach R, Loman N, Olsson HK, Meltzer P et al. 2003 Molecular classification of familial non-BRCA1/BRCA2 breast cancer. PNAS 100 2532-2537. (doi:10.1073/pnas. 0533805100)
18. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al. 2005 Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 455-462. (doi:10.1016/S0140-6736(05)67059-6)
19. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R & Grohé C 2000 Estrogen receptor rapidly activates the IGF-1 receptor pathway. Journal of Biological Chemistry 275 18447. (doi:10.1074/jbc.M910345199)
20. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, GreenMet al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology 26 1275-1281. (doi:10.1200/JCO.2007.14.4147)
21. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H, Hortobagyi GN, Piccart-Gebhart M, Sotiriou C et al. 2009 Genomic grade index isassociated with response to chemotherapy in patients with breast cancer. Journal of Clinical Oncology 27 3185-3191. (doi:10.1200/JCO.2008.18. 5934)
22. Loboda A, Nebozhyn M, Cheng C, Vessey R, Huang P, Dai H & Watters JW 2009 Biomarker discovery: identification of a growth factor gene signature. Clinical Pharmacology and Therapeutics 86 92-96. (doi:10.1038/clpt.2009.48)
23. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA et al. 2007 Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. Journal of Clinical Oncology 25 1239-1246. (doi:10.1200/JCO.2006. 07.1522)
24. Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK & Kreipe H 2002 Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. Journal of Pathology 198 292-299. (doi:10.1002/path.1218)
25. Miller WR & Larionov A 2011 Molecular effects of oestrogen inhibition in breast cancer. Molecular and Cellular Endocrinology 340 127-136.
26. Miller WR, White S, Dixon JM, Murray J, Renshaw L & Anderson TJ 2006 Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. British Journal of Cancer 94 1051-1056. (doi:10.1038/sj.bjc.6603001)
27. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, Sing T, Evans DB & Dixon JM 2009 Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. Journal of Clinical Oncology 27 1382-1387. (doi:10.1200/JCO.2008.16.8849)
28. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes JF, Price KN et al. 2009 Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New England Journal of Medicine 361 766-776. (doi:10.1056/ NEJMoa0810818)
29. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T et al. 2004 A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine 351 2817-2826. (doi:10.1056/NEJMoa041588)
30. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z et al. 2009 Supervised risk predictor of breast cancer based on intrinsic subtypes. Journal of Clinical Oncology 27 1160-1167. (doi:10.1200/JCO.2008.18.1370)
31. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA et al. 2000 Molecular portraits of human breast tumours. Nature 406 747-752. (doi:10.1038/35021093)
32. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW & Ellis IO 2008 Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. Journal of Clinical Oncology 26 3153-3158. (doi:10.1200/JCO.2007.15.5986)
33. Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I & Walsh G 2005 Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. Journal of Clinical Oncology 23 5108-5116. (doi:10.1200/JCO.2005.04.005)
34. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS et al. 2001 Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS 98 10869-10874. (doi:10.1073/pnas.191367098)
35. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B et al. 2006 Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. Journal of the National Cancer Institute 98 262-272. (doi:10.1093/jnci/djj052)
36. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES et al. 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. PNAS 102 15545-15550. (doi:10.1073/pnas.0506580102)
37. van 't Veer LJ 2002 Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 530-536. (doi:10.1038/415530a)
38. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schutz F et al. 2008 Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Research 10 R65. (doi:10.1186/bcr2124)